Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ~7% of human malignancies and ~60% of melanomas(1). Early clinical experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumour response rate among patients with B-RAF(V600E)-pos...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Nazarian, Ramin, Shi, Hubing, Wang, Qi, Kong, Xiangju, Koya, Richard C., Lee, Hane, Chen, Zugen, Lee, Mi-Kyung, Attar, Narsis, Sazegar, Hooman, Chodon, Thinle, Nelson, Stanley F., McArthur, Grant, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3143360/
https://ncbi.nlm.nih.gov/pubmed/21107323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09626
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares